Earnings Insights · HUM · Q3 FY2026
Humana Q3 2026 Earnings: Guidance Rises as Medical Costs Track Better Than Expected
By AlgovestIQ ResearchPublished
Read Humana’s results announcement (Form 8-K, filed Nov 6, 2026)
Key earnings findings
Humana (HUM) Q3 FY2026 · results discussed on the earnings call · Form 8-K filed
- Humana reported Q3 FY2026 revenue of $41.16B against the $40.87B analyst estimate, a 0.7% beat, and EPS of -$0.70 against the -$1.00 analyst estimate, a 30.0% beat.
- Adjusted results were weaker, with a $0.70 loss per share versus adjusted EPS of $3.24 in the prior-year quarter, reflecting an adjusted pretax loss in the Insurance segment despite a medical benefit ratio that was modestly better than management’s outlook.
- HUM closed at $433.74 on Nov 6, 2026, up 5.3% from $411.79 on Nov 5, 2026, the last close before the results were released.
Sources: Humana results announcement (SEC), the Q3 FY2026 earnings call, and AlgovestIQ reported-results and market data. All references
Did Humana beat earnings expectations?
- EPS has beaten the estimate in all 8 of the most recent reported quarters on record.
- Revenue surprise across the last 8 reported quarters has ranged from -0.3% to 2.0%.
Reported figures against analyst estimates, compiled from AlgovestIQ data.
Humana reported third-quarter revenue of $41.2B, up from $32.6B a year earlier, while GAAP EPS fell to $1.33 from $1.62. Adjusted results were weaker, with a $0.70 loss per share versus adjusted EPS of $3.24 in the prior-year quarter, reflecting an adjusted pretax loss in the Insurance segment despite a medical benefit ratio that was modestly better than management’s outlook.
The more important development was the increase in full-year adjusted EPS guidance to at least $9.50 from at least $9.00. Management said medical-cost trends have tracked at or better than expectations, supported by favorable inpatient utilization and Part D performance, while 2027 Medicare Advantage pricing and product positioning should support a material margin recovery.
Earnings Snapshot
| Metric | Reported | Change |
|---|---|---|
| Consolidated revenue | $41.2B | Up 26% from $32.6B |
| GAAP EPS | $1.33 | Down from $1.62 |
| Adjusted EPS | ($0.70) | Down from $3.24 |
| GAAP pretax income | $216M | Up from $134M |
| Adjusted pretax loss | ($104M) | Down from $527M income |
| Insurance segment operating loss, GAAP | ($303M) | Down from $251M income |
| Insurance segment operating loss, adjusted | ($299M) | Down from $270M income |
| Insurance segment GAAP benefit ratio | 93.7% | Better than guidance for slightly above 94% |
| Consolidated operating cost ratio, GAAP | 11.3% | Improved from 12.6% |
| Consolidated operating cost ratio, adjusted | 11.2% | Improved from 11.8% |
| Year-to-date revenue | $121.7B | Up from $97.1B |
| Year-to-date GAAP EPS | $16.84 | Up from $16.43 |
| Year-to-date adjusted EPS | $17.17 | Down from $21.10 |
The Bigger Story
Humana’s quarter showed an important split between current reported profitability and the company’s improving outlook for its Medicare Advantage business.
The Insurance segment posted an adjusted operating loss of $299M, compared with adjusted income of $270M a year earlier. Yet management raised its full-year outlook, citing medical-cost performance that has been better than expected and actions taken to offset the 2026 Medicare Advantage Star Ratings headwind.
The central earnings-recovery thesis now rests on three factors: pricing and benefit changes for 2027 Medicare Advantage plans, continued cost transformation, and a recovery in quality-bonus revenue beginning with the 2028 bonus year. Management said it expects meaningful Medicare Advantage margin improvement in 2027, although it did not provide a specific margin target.
Humana also reported sharply stronger 2028 Star Ratings results, with a member-weighted rating of 4.17. Management said these results exceed its top-quartile performance objective and could create a one-time earnings tailwind in 2028. Management also said it expects 2027 margin progression to put Humana on track for a margin of 3% or more in 2028. It said it remains on track for its 2028 Investor Day commitments and will update them at an investor event on December 10. However, the company expects to allocate part of that upside toward quality, customer experience, and clinical investments, while sharing some through to earnings and shareholders. The eventual financial benefit will depend on membership, competitive ratings performance, and the ultimate mix of plans.
Revenue and Operating Performance
Revenue increased 26% year over year to $41.2B in the third quarter and rose 25% year to date to $121.7B. Adjusted revenue was effectively unchanged from reported revenue, as the only adjustment was a $3M impairment charge.
The reported revenue growth did not translate into higher Insurance segment earnings. The segment’s adjusted operating result swung to a $299M loss from $270M of income in the prior-year period. That contrast illustrates the pressure still facing Medicare Advantage margins after lower Star Ratings reduced bonus payments for 2026.
There were nevertheless signs of operating improvement. Humana’s Insurance segment benefit ratio was 93.7%, modestly better than management’s expectation for a ratio slightly above 94%. Management said medical-cost trends were at the lower end of its expected 7% to 8% range for 2026, aided by better-than-expected inpatient utilization and lower costs per admission.
Part D performance was also favorable in 2026 and contributed to the increased earnings outlook. That benefit is not expected to repeat at the same rate next year. Management expects Part D trend to rise to 14% to 15% in 2027, versus approximately 11% to 12% in 2026, due largely to a stronger healthcare technology pipeline.
CenterWell Senior Primary Care continued to expand, with year-to-date patient growth of 146,800, or 30%, including the first-quarter MaxHealth acquisition. Management also acknowledged pressure in one CenterWell geography involving a particular patient population and several Florida facilities. It said CenterWell, Humana, and other payers have taken contracting, benefit-design, and network-management actions that should address most of the pressure.
Medicaid membership rose by 103,600 year to date, or 7%, driven primarily by integrated dual-eligible programs in Michigan, Illinois, and South Carolina. Humana now has a Medicaid footprint spanning 13 states, including active operations in 11 states and pending implementations in Georgia and Texas.
Profitability and Margins
Humana’s reported GAAP and adjusted earnings told very different stories in the quarter.
GAAP pretax income increased to $216M from $134M, but GAAP EPS declined to $1.33 from $1.62. Adjusted pretax results moved to a $104M loss from $527M of income, producing an adjusted loss per share of $0.70.
The largest difference between GAAP and adjusted results was a $358M non-cash put/call valuation adjustment related to minority investments in Humana’s primary-care strategic partnership. That adjustment reduced GAAP EPS by $2.94 in the quarter but is excluded from management’s adjusted performance measure. The quarter also included $25M of value-creation initiative costs, primarily associated with Humana’s multiyear transformation program.
While Insurance profitability remained under pressure, expense management improved. The consolidated adjusted operating cost ratio fell 60 basis points year over year to 11.2%. Management described the transformation program as an ongoing source of operating and medical-cost improvement, although it did not quantify expected savings for 2027.
Management said it remains on track to double individual Medicare Advantage pretax margin in 2026 excluding the Star Ratings headwind. It also said 2027 margin improvement should be driven primarily by pricing, with additional support from lower onboarding costs associated with fewer new members, transformation efforts, and the continued maturation of Medicaid and primary-care investments.
Demand, Customers and Pricing
Humana said its 2026 membership, including both new and returning members, is performing in line with or better than expectations. Early results from the 2027 annual enrollment period have also been better than management initially expected.
Management expects Medicare Advantage membership to increase in 2027, although it cautioned that enrollment is still early and retention data remain incomplete. Strong retention of members affected by planned plan exits and better-than-planned new sales have supported the early outlook.
The company attributed much of its early enrollment performance to stronger relationships with distribution partners. Management also said industry plan exits appear to be consolidating enrollment among larger Medicare Advantage carriers.
For 2027, management said its first bidding priority was pricing for margin, followed by retention and then growth. That ordering matters: Humana is signaling that it is willing to prioritize profitability over enrollment expansion as it works toward its longer-term margin target.
What Is Humana’s Guidance for FY 2026?
Humana raised its full-year 2026 adjusted EPS guidance to at least $9.50, from its previous expectation of at least $9.00. The company raised GAAP EPS guidance to at least $15.09, from at least $6.52 previously.
The substantial change in GAAP guidance does not represent a comparable increase in operating earnings. It includes the effect of non-cash valuation changes associated with minority-interest investments and reflects a reversal of the approximately $1.2B net put liability tied to CenterWell Senior Primary Care’s previous joint ventures with Welsh, Carson, Anderson & Stowe.
Management said the full-year adjusted outlook reflects medical-cost trends that are in line with or better than expectations. The guidance still implies a year-over-year adjusted EPS decline from $17.14 in 2025, primarily because of the 2026 Star Ratings headwind, net of mitigation efforts.
Looking into 2027, management expects core medical-cost trend of 8% to 9%, up from 7% to 8% in 2026. It said that expected trend has been incorporated into Medicare Advantage and prescription drug plan bids.
Balance Sheet, Cash Flow and Capital
Humana continued to restructure its primary-care ownership arrangements through a new joint venture with BlackRock’s HPS Investment Partners business, replacing prior ventures with Welsh, Carson, Anderson & Stowe.
Management said the new structure reduces the cost of capital and should lower Humana’s GAAP debt-to-capital ratio by roughly 130 basis points in the fourth quarter. The structure also eliminates the need to fund a previously pending put option in 2027, which management said would have increased the debt-to-capital ratio by about 130 basis points if debt-funded.
Humana expects to record a non-cash initial option liability associated with the BlackRock venture in the fourth quarter. The company estimates the item will reduce GAAP EPS by $2.14, but it plans to exclude the charge from adjusted EPS because it stems from the transaction’s ownership and option structure.
The company also expects to complete the divestment of its minority interest in Gentiva during the fourth quarter, generating approximately $900M of pretax proceeds.
Management said capital priorities remain funding growth in the regulated insurance subsidiaries, Medicaid, and CenterWell. It expects to resume dividend growth as earnings recover and to increase repurchases beyond offsetting dilution over time, although it emphasized that buybacks are relatively demanding from a debt-to-capital perspective.
What Investors Should Watch
1. Medicare Advantage Margin Recovery in 2027
Management expects a material improvement in Medicare Advantage profitability next year, primarily from pricing and product changes. The key test will be whether those actions offset higher medical-cost trend while preserving enrollment and retention.
2. Medical Cost Trend and Part D Inflation
Inpatient utilization and Part D costs were favorable in 2026, helping support the higher full-year outlook. For 2027, Humana expects higher core trend and Part D cost growth of 14% to 15%; actual claims experience will determine whether pricing proves sufficient.
3. Medicare Advantage Enrollment and Retention
Early annual enrollment period activity has been encouraging, but management has not yet quantified 2027 membership growth. Retention results will be particularly important because Humana’s margin outlook partly depends on lower new-member acquisition and onboarding costs.
4. Star Ratings Monetization
The 4.17 member-weighted rating for the 2028 bonus year is a meaningful operational improvement. Investors should watch how much of the eventual financial tailwind is retained in earnings after provider-sharing arrangements, reinvestment, competitive changes, and management’s planned return of some benefit to shareholders.
5. CenterWell and Medicaid Execution
CenterWell patient growth and Medicaid expansion broaden Humana’s care-delivery and government-program footprint, but both businesses remain in investment and maturation phases. Improvement in CenterWell’s pressured geography and progress through the Medicaid and primary-care “J-curves” will determine how quickly these businesses contribute to consolidated earnings.
AlgovestIQ Takeaway
Humana’s third quarter did not show a clean earnings recovery in reported operating results. The Insurance segment remained loss-making on an adjusted basis, and adjusted EPS fell sharply year over year. But the benefit ratio, operating-cost ratio, and management’s updated full-year outlook indicate that 2026 medical costs are developing more favorably than the company had expected.
The investment case has become more dependent on execution in 2027. Humana is positioning its Medicare Advantage products for higher margins, expects enrollment growth rather than the earlier possibility of flat-to-down membership, and sees further savings from transformation efforts. Those factors could improve profitability even before the improved Star Ratings affect payment rates in 2028.
The stronger 2028 Star Ratings result is strategically significant, but investors should avoid treating the full benefit as recurring earnings power. Management intends to operate the business around a sustainable top-quartile quality level rather than its current above-target result, and it expects to reinvest part of the temporary upside.
The key question is whether Humana can convert better pricing, medical-cost discipline, and quality improvement into durable Medicare Advantage margin expansion without sacrificing competitive membership growth. Evidence of stable 2027 claims trends, solid retention through the enrollment period, and improving profitability at CenterWell and Medicaid would strengthen that case. Conversely, higher-than-priced medical costs, weak retention, or a need for heavier reinvestment of Star Ratings gains would limit the pace of the recovery.
How did HUM stock react?
HUM closed at $433.74 on Nov 6, 2026, up 5.3% from $411.79 on Nov 5, 2026, the last close before the results were released.
| Session | Close | Change |
|---|---|---|
| Nov 5, 2026 (before release) | $411.79 | — |
| Nov 6, 2026 | $433.74 | +5.3% |
| Nov 9, 2026 | $423.22 | +2.8% |
Closing prices from AlgovestIQ market data. A move around a report also reflects the wider market.
More from this earnings season
- CIThe Cigna Group Q3 2026 Earnings: Cigna Healthcare Offsets Pressure in Pharmacy BenefitsNov 5, 2026
- OSCROscar Health Q3 2026 Earnings: Underwriting Gains Drive Another Outlook IncreaseNov 5, 2026
- CVSCVS Health Q3 2026 Earnings: CVS Plans Separation as Aetna Margin Recovery Lifts GuidanceNov 4, 2026
- ELVElevance Health Q3 2026 Earnings: Higher 2026 Outlook Masks Modest Underlying Revenue GrowthOct 21, 2026
- UNHUnitedHealth Group Q3 2026 Earnings: Profit Recovery Drives Higher Full-Year EPS OutlookOct 13, 2026
References
- Management commentary, analyst questions and outlook discussed on the call. Source: Humana Q3 FY2026 earnings call transcript, as of Nov 6, 2026.
- Reported results, segment figures and guidance from the company's results announcement. Source: Humana Form 8-K, Item 2.02 (SEC EDGAR), as of Nov 6, 2026.
- Reported revenue and EPS against analyst estimates, and the reported quarterly series. Source: AlgovestIQ reported-results data, as of Nov 6, 2026.
AI-generated analysis based on company-reported earnings data and earnings-call materials. Not investment advice.